<DOC>
	<DOCNO>NCT00799825</DOCNO>
	<brief_summary>This phase 3b study design ass safety GlaxoSmithKline Biological 's HPV vaccine GSK580299 female subject take part study 580299/008 receive control vaccine ( Hepatitis A vaccine ) .</brief_summary>
	<brief_title>Safety Study GSK Biologicals ' Human Papillomavirus Vaccine 580299/008 Subjects From Canada US</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study A subject previously enrol primary study ( NCT00122681 ) , receive active control hepatitis A vaccine , receive commercially available HPV16/18 L1 VLP AS04 vaccine vaccine yet grant licensure subject 's country subject age vaccine license . Written informed consent must obtain subject prior enrolment . A woman age 18 year old , time first vaccination study . Healthy subject establish medical history clinical examination enter study . Subjects must pregnant . Absence pregnancy verify urine pregnancy test . Subject must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Pregnant lactate female . Enrolment defer three month pregnancy complete lactate cease . A woman plan become pregnant likely become pregnant ( determined investigator ) planning discontinue contraceptive prevention study period two month last vaccine dose . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period extend safety followup period . Concurrently participate another clinical study time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous vaccination HPV plan administration another HPV vaccine study foreseen protocol . Planned administration/ administration vaccine foreseen study protocol within 30 day ( i.e . Day 029 ) dose vaccine . Administration routine meningococcal , hepatitis B , hepatitis A , inactivated influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day dose study vaccine allow . Enrolment defer subject outside specify window . Previous administration component investigational vaccine . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex . Acute chronic , clinically significant pulmonary , cardiovascular , neurologic , haematological , hepatic renal functional abnormality , determine previous physical examination laboratory test , opinion investigator precludes administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Cancer autoimmune disease treatment . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Acute disease time enrolment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>papillomavirus</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>HPV</keyword>
	<keyword>human papillomavirus</keyword>
</DOC>